Abstract
Background/Aims: Defective DNA mismatch repair (MMR) in pancreatic cancer, reported in up to 13% of sporadic pancreatic cancers, may predict a good prognosis. To determine if long-term survival in pancreatic cancer could be attributed to defective DNA MMR, we ascertained its prevalence in 35 pancreatic cancer patients who survived ≥ 3 years after surgery. Methods: We performed immunohistochemistry (IHC) for MMR proteins hMLH1, hMSH2, and hMSH6 in all 35 tumors and microsatellite instability (MSI) studies in 34/35 tumors using 10 microsatellite markers in paired normal and tumor DNA. Defective DNA MMR was defined as absence of protein expression on IHC and/or MSI in ≥ 30% of markers studied. Results: On IHC, 3/35 (8.6%) tumors had defective DNA MMR. All 3 had absent expression of a DNA MMR protein (hMLH1 in 2 and hMSH2) and 2/3 also had MSI; the third could not be tested. Definitely 2, and probably all 3 patients had hereditary non-polyposis colon cancer as determined by clinical and genetic profiles. Conclusion: Defective DNA MMR is uncommon in long-term survivors of pancreatic cancer and does not account for the survival benefit in those with sporadic pancreatic cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 220-228 |
Number of pages | 9 |
Journal | Pancreatology |
Volume | 5 |
Issue number | 2-3 |
DOIs | |
State | Published - 2005 |
Keywords
- DNA mismatch repair
- Microsatellite instability
- Pancreatic neoplasms
- Prognosis
- hHMSH2
- hMLH1
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Gastroenterology